

**Table SII. Mean methotrexate (MTX) and folate weekly doses according to patients and prescribers characteristics**

	MTX dose Mg/week Median [IQR]	<i>p</i> -value	Folate dose Mg/week Median [IQR]	<i>p</i> -value
Sex		< 0.001		0.23
Male	13.1 [9.5–17.0]		10.5 [4.6–16.7]	
Female	11.8 [9.0–15.5]		10.6 [4.7–17.1]	
Age at MTX initiation		< 0.001		< 0.001
<40 years	12.1 [8.9–17.0]		8.9 [0.5–16.4]	
40–49 years	12.6 [9.3–16.6]		10.4 [3.8–16.2]	
50–59 years	12.3 [9.4–15.7]		10.9 [5.3–16.5]	
60–69 years	12.6 [9.6–16.3]		10.7 [6.0–16.9]	
≥70 years	11.7 [9.0–15.3]		11.3 [5.6–18.5]	
Underlying disease		< 0.001		< 0.001
Rheumatoid arthritis	12.3 [9.4–15.5]		10.4 [6.0–15.2]	
Psoriasis/psoriatic arthritis	12.5 [9.2–16.9]		10.9 [2.7–19.1]	
Crohn's disease or ulcerative colitis	14.9 [9.2–21.6]		13.4 [6.5–23.3]	
Combination of several diseases	11.8 [8.6–15.5]		10.5 [5.8–15.9]	
Other or unknown	12.2 [9.5–16.6]		9.9 [0–18.9]	
MTX prescriber specialty		0.01		< 0.001
Rheumatologist	12.4 [9.3–15.6]		10.5 [5.5–15.6]	
General practitioner	11.9 [9.0–16.5]		10.6 [3.7–17.9]	
Dermatologist	13.5 [9.2–17.2]		12.5 [3.6–23.3]	
Gastroenterologist	16.9 [9.1–21.4]		14.4 [5.7–23.5]	
Internist	12.7 [10.4–17.9]		11.7 [5.8–17.9]	
Other	11.7 [8.9–15.8]		9.4 [0–17.7]	

IQR: interquartile range.